Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charming Medical Limited Class A ( (MCTA) ) has provided an announcement.
On April 2, 2026, Charming Medical Limited appointed Matthew Mo Kan Tsui as an independent director with annual compensation of HK$384,000, with his term to continue until a successor is elected or he leaves the role. The board determined that Tsui meets U.S. SEC and Nasdaq independence standards, is an audit committee financial expert, and will serve as a non‑employee director, underscoring the company’s emphasis on financial sophistication and regulatory compliance.
Tsui was simultaneously named chairman of the Audit Committee and a member of the Compensation and Nominating Committees, concentrating key oversight responsibilities in a veteran finance professional. With more than 20 years’ experience in accounting, corporate finance, and capital markets, including senior roles at KPMG and Hong Kong‑listed companies, his appointment is expected to strengthen Charming Medical’s internal controls, risk management, and ESG‑related governance, which could enhance confidence among investors and other stakeholders.
More about Charming Medical Limited Class A
Charming Medical Limited is a Hong Kong‑based company listed in the U.S. as a foreign private issuer, operating in the medical sector. The company is subject to U.S. Securities and Exchange Commission and Nasdaq rules, reflecting a capital‑markets focus that requires robust financial reporting, governance, and board‑level oversight structures.
Technical Sentiment Signal: Strong Sell
Current Market Cap: $504.3M
For a thorough assessment of MCTA stock, go to TipRanks’ Stock Analysis page.